SIGA

SIGA Technologies Inc. - 10-KSB Summary (Fiscal Year Ended Dec 31, 2002)

Business Context and Reporting Period

Company: SIGA Technologies, Inc.
Reporting Period: Fiscal year ended December 31, 2002.
Status: Development-stage biotechnology company incorporated in Delaware (1996).
Focus: Discovery and development of vaccines, antibiotics, and anti-infectives for serious infectious diseases. Key programs include a mucosal vaccine for strep throat, anti-infectives targeting drug-resistant bacteria, and biological defense products (e.g., smallpox antivirals).
Operations: Headquarters in New York, NY; R&D facilities in Corvallis, OR. As of March 2003, the company employed 17 full-time staff.

Key Financial Metrics

Note: Revenues are derived primarily from government grants (NIH SBIR) and research contracts. The company has no commercial product sales.

Material Changes vs. Prior Period

• Revenue Decline: Revenues decreased approximately 70% to $344,450 from $1.16 million in 2001. The 2001 figure included a one-time recognition of $562,500 in deferred revenue from Wyeth. 2002 revenue was driven by a $270,000 NIH SBIR grant and $75,000 from an Oregon State University subcontract.
• Expense Reduction: General and administrative (G&A) expenses decreased 28% to $1.84 million, largely due to a reduction in executive management staff and the absence of a $612,750 non-cash stock option charge recorded in 2001. Research and development (R&D) expenses remained relatively flat, increasing slightly to $1.77 million.
• Capital Structure: The company raised approximately $2.8 million in gross proceeds through private placements in late 2002 (October and December), issuing common stock and warrants. All convertible debentures outstanding in 2001 were converted to equity by the end of 2001, eliminating related interest expense in 2002.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management believes current resources ($2.07 million cash plus $792,000 in stock subscriptions) are sufficient to fund operations through the first quarter of 2004. Additional financing will be required to continue development.
• New Contracts: In December 2002, SIGA secured a four-year contract with the U.S. Army to develop a smallpox antiviral drug, estimated at $1.6 million total revenue (approx. $400,000/year), effective January 1, 2003.
• Development Status: The strep throat vaccine is in Phase I clinical trials. All other programs (antibiotics, biological defense) are in pre-clinical stages. Commercialization is not expected for several years, if at all.
• Risks:
  • Going Concern: The company has incurred cumulative losses of $29.5 million since inception and expects to continue incurring losses.
  • Regulatory: No products have received FDA approval. Success depends on rigorous clinical testing and regulatory clearance.
  • Acquisition Strategy: The company terminated a planned acquisition of Allergy Therapeutics in July 2002, incurring approximately $600,000 in expenses (with $200,000 remaining unpaid). A non-binding letter of intent to acquire Plexus Vaccines was signed in March 2003.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $2.07 million cash balance to sustain operations through Q1 2004 given the burn rate.
• Revenue Recognition: Confirm the timing and conditions for revenue recognition under the new U.S. Army contract and NIH grants.
• Stock Dilution: Review the impact of recent private placements and outstanding warrants (approx. 4.7 million warrants) on future share count.
• Acquisition Costs: Assess the financial impact of the $200,000 unpaid liability from the failed Allergy Therapeutics acquisition.
• Key Personnel: Monitor the retention of Dr. Dennis Hruby (Chief Scientific Officer), identified as a key employee whose departure would materially harm the business.